CN113528474B

CN113528474B - 3-sterone-delta1Dehydrogenase and coding gene and application thereof

Info

Publication number: CN113528474B
Application number: CN202111095415.8A
Authority: CN
Inventors: 张瑞; 王玉; 冯进辉; 陈曦; 姚培圆; 吴洽庆; 朱敦明; 马延和
Original assignee: Tianjin Institute of Industrial Biotechnology of CAS
Current assignee: Tianjin Pharmaceutical Co ltd; Tianjin Institute of Industrial Biotechnology of CAS
Priority date: 2021-09-17
Filing date: 2021-09-17
Publication date: 2021-12-10
Anticipated expiration: 2041-09-17
Also published as: CN113528474A

Abstract

The invention provides 3-sterone-delta¹Dehydrogenase, its coding gene and application, and provides an expression vector containing its gene and a genetically engineered recombinant strain containing the expression vector. The 3-sterone-delta provided by the invention¹The dehydrogenase is a novel 3-sterone-delta¹Dehydrogenases, which have a broad substrate spectrum and have a high activity on most 3-ketosteroids. The recombinant strain provided by the invention can be used for converting 3-ketosteroid compounds, obtains a target product with high yield by high substrate feeding concentration, has no by-product, has a conversion rate of not less than 94 percent, short conversion time, small using amount of used biocatalyst, simple and convenient preparation method, mild conditions, environmental protection and good industrialization prospect.

Description

3-sterone-delta1Dehydrogenase and coding gene and application thereof

Technical Field

The invention belongs to the technical field of genetic engineering and enzyme engineering, and particularly relates to 3-sterone-delta¹Dehydrogenases and their use.

Background

Steroid drugs have strong pharmacological actions such as anti-infection, anti-allergy, anti-virus and anti-shock, and have become the second main class of drugs second to antibiotics. Classification of steroid hormones drugs: adrenocortical hormones including hydrocortisone, prednisone, etc., for treating Addison's disease, anti-inflammatory, antiallergic, antishock, etc.; the protein assimilation hormone has the main physiological functions of inhibiting protein dissimilation and promoting protein synthesis, and is mainly used for treating diseases caused by protein increase and synthesis deficiency; sex hormones, including estrogen, androgen and progestin.

The anti-inflammatory activity can be increased by times after a double bond is introduced into the C1, 2-position of the A ring of the steroid drug parent nucleus, at present, the production of a plurality of clinically important steroid compounds is commonly used, particularly, the production of most of adrenocortical hormones with anti-inflammatory capability relates to dehydrogenation reaction of C1, 2-position, and comprises prednisolone (prednisolone), dexamethasone (dexamethasone), paramethasone (paramethasone), betamethasone (betamethasone), fluocortolone (fluocortolone), fluocinolone (fluocinolone), triamcinolone (triamcinolone), methylprednisolone (medrol) and the like. Methods for the 1, 2-position dehydrogenation of steroids generally include chemical methods and microbial fermentation methods. The chemical dehydrogenation generally needs to use SeO2, has low yield, has great environmental pollution caused by SeO2, and is gradually replaced by a biological method at present. The microorganism fermentation dehydrogenation method, which is currently applied to a large number of strains, is arthrobacter (CN 101760495, CN 200710060202), and although the defects of the chemical method are avoided, the method has the defects of low substrate concentration, long conversion time, low conversion rate and yield, difficult separation and purification and the like.

3-sterone-delta¹Dehydrogenase (3-ketosteroid-. DELTA.¹-dehydrogenases, KsdD), a flavoprotein-dependent dehydrogenase, which can catalyze the dehydrogenation of carbon-carbon single bond (C-C) at 1-and 2-positions of a ring a of 3-ketosteroid mother nucleus to carbon-carbon double bond (C ═ C) by taking Flavin Adenine Dinucleotide (FAD) as a cofactor in the catalytic reaction process, and has a broad application prospect, as shown in the following figure.

3-sterone-delta¹The dehydrogenase is widely existed in microorganisms, and 3-sterone-delta is continuously prepared and obtained from different microorganism cells¹Dehydrogenase, 1990 by Itagaki et alNocardia corallinaKsdD is obtained by purification, the activity of the enzyme to various substrates is measured, and the enzyme activity is reduced after C11 position of C19 type compound androst-4-ene-3, 17-diketone (4-AD) is replaced by carbonyl, and the activity is basically not high after C11 position is replaced by hydroxyl; for the C21 compound 17 alpha, 21-bishydroxypregn-4-ene-3, 20-dione (cortixolone), the enzyme activity was increased to some extent when the C11 position was substituted with a carbonyl group, while the C11 position was substituted with a hydroxyl group and was substantially inactive [ Itagaki E, Hatta T, Wakabayashi T& Suzuki K. Spectral properties of 3-ketosteroid-Δ¹-dehydrogenase from Nocardia corallina. Biochim Biophys Acta1990, 1040:281-286 ]. Subsequently, in 1995, Choi et al willArthrobacter simplexIn (1)kstDThe genes construct shuttle plasmidsStreptomyces lividansThe method carries out heterologous expression, and researches on enzymology property and substrate spectrum, and the experimental result shows that the catalytic activity of the enzyme is greatly reduced after the steroid nucleus C11 is replaced by hydroxyl [ Choi KP, Moln a r T, Yamashita M& Murooka Y. Purification and characterization of the 3-ketosteroid-Δ¹-dehydrogenase of Arthrobacter simplex produced in Streptomyces liuidans. J Biochem1995, 117: 1043-. In 2007, the Lufuping subject group willArthrobacter simplexIn (1)kstDThe gene is expressed in the bacillus subtilis through a vector pWB980, and the intracellular and extracellular enzyme activities are respectively 0.11U/mg and 0.015U/mg by taking 4-AD as a substrate. 1 g/L of substrate 4-AD is transformed by using the bacillus subtilis recombinant cells, and the maximum transformation rate reached by 40 h of transformation is only 45.5% [ Li Y, Lu F, Sun T& Du L. Expression of ksdD gene encoding 3-ketosteroid-∆¹-dehydrogenase from Arthrobacter simplex in Bacillus subtilis. Letters in Applied Microbiology2007, 44:563-568 ]. In 2013, the group of questions related to the symptomatology willMycobacterium neoaurumInksdDThe gene is expressed in the bacillus subtilis, and the intracellular is measured by taking 4-AD as a substrateThe exoenzyme activity was 1.75U/mg and 0.08U/mg, respectively. 1 g/L substrate 4-AD is transformed by using the bacillus subtilis recombinant cells, and the maximum transformation rate reached by 10H of transformation is only 65.7% [ Zhang WQ, Shao ML, Rao ZM, Xu MJ, Zhang X, Yang TW, Li H& Xu ZH. Bioconversion of 4-androstene-3,17-dione to androst-1,4-diene-3,17-dione by recombinant Bacillus subtilis expressing ksdd gene encoding 3-ketosteroid-∆¹-dehydrogenase from Mycobacterium neoaurum JC-12. J Steroid Biochem Mol Biol, 2013, 135:36-42】。

In summary, the current 3-sterone-delta¹The dehydrogenase has low activity on steroid drug intermediates, particularly on intermediates substituted by related bond groups at C11 on steroid parent nucleus, even has no activity, so that the dehydrogenase still has the problems of low substrate feeding concentration, low conversion rate and the like when being applied to the synthesis of steroid C1 and 2 dehydrogenation drug intermediates.

Therefore, KsdD enzyme gene resources are fully excavated, and 3-ketosteroid-delta with high activity to most steroid substrates is screened¹Dehydrogenase and application in the synthesis of steroid C1, 2-position dehydrogenation drug intermediate, which is a key requirement for the industrialization of steroid enzyme process.

Disclosure of Invention

In order to overcome the problems of the prior art, the invention aims to provide a novel 3-sterone-delta¹Dehydrogenase and its coding gene and application to solve the problem of 3-sterone-delta¹The dehydrogenase has lower activity to steroid drug intermediate, the substrate feeding concentration is small when in use, the conversion rate is low and the like.

In order to achieve the purpose, the invention adopts the following technical scheme:

in a first aspect of the invention, there is provided a 3-sterone- Δ¹A dehydrogenase, said 3-sterone-Delta¹The dehydrogenase is a protein of the following (1) or (2); (1) the amino acid sequence is shown as SEQ ID NO: 1; (2) a protein having at least 80%, at least 90%, at least 95%, at least 99% homology with the protein of (1) and having the function of the protein of (1).

Most preferably, the 3-sterone- Δ¹The amino acid sequence of the dehydrogenase is as set forth in SEQ ID NO: 1 is shown.

In a second aspect of the present invention, there is provided a polynucleotide encoding the aforementioned 3-sterone- Δ¹A dehydrogenase. Preferably, the encoding is the aforementioned 3-sterone-delta¹The nucleotide sequence of the polynucleotide of the dehydrogenase is as set forth in SEQ ID NO: 2, respectively.

In a third aspect of the invention, there is provided a genetically engineered expression vector comprising the polynucleotide as described above. Methods well known to those skilled in the art can be used to construct the recombinant expression vectors. These methods include recombinant DNA techniques, DNA synthesis techniques and the like. Can encode the 3-sterone-delta¹The DNA of the dehydrogenase is operatively linked to a multiple cloning site in the vector to direct the synthesis of mRNA for the expression of 3-sterone-Delta¹Dehydrogenase, or for homologous recombination. In a preferred embodiment of the present invention, pET-21a is used as the expression vector.

In a fourth aspect of the invention, a genetically engineered expression strain is provided, which comprises the recombinant expression vector or a polynucleotide having an exogenous sequence integrated into its genome.

In a preferred embodiment of the invention, the genetically engineered expression strain is escherichia coli. The Escherichia coli is preferably BL21(DE 3).

The present invention also provides the aforementioned 3-sterone-Delta¹-dehydrogenase or 3-sterone-delta¹-dehydrogenase gene engineering expression of strains in delta of 3-ketosteroids¹-use in dehydrogenation reactions.

The application is that 3-keto steroid compound is used as a substrate, an electron acceptor is added, preferably the electron acceptor is phenazine methyl sulfate or 1, 4-naphthoquinone, and conversion reaction is carried out to obtain C1, 2-dehydrosteroid compound; the 3-ketosteroid compound is one of the following compounds: androst-4-ene-3, 17-dione; androst-4-ene-3, 11, 17-trione; androsta-4, 9(11) -diene-3, 17-dione; 17 β -hydroxyandrost-4-ene-3, 17-dione; pregn-4-ene-3, 20-dione; 4-pregnene-3, 11, 20-trione; 17 α -hydroxypregn-4-ene-3, 20-dione; 17 α, 21-bishydroxypregn-4-ene-3, 20-dione; 17 α, 21-bishydroxypregn-4-ene-3, 11, 20-trione; 11 β,17 α, 21-trihydroxypregn-4-ene-3, 20-dione; 11 beta, 17 alpha, 21-trihydroxypregn-4-ene-3, 20-dione-21-acetate; 21-hydroxy-pregna-4, 9(11), 16-triene-3, 20-dione-21-acetate.

The invention also provides a method for preparing the C1, 2-dehydrogenation steroid compound, which comprises the following steps: the 3-sterone-delta of the first aspect of the invention¹The dehydrogenase or the gene engineering expression strain of the fourth aspect acts on the 3-ketosteroid compound, and simultaneously an electron acceptor is added, the conversion is carried out at 25-35 ℃, preferably 30 ℃, and the C1, 2-dehydrosteroid compound is obtained after the conversion time is 6-24 hours.

In a preferred embodiment of the present invention, the 3-ketosteroid compound is one of the following compounds: androst-4-ene-3, 17-dione; androst-4-ene-3, 11, 17-trione; androsta-4, 9(11) -diene-3, 17-dione; 17 β -hydroxyandrost-4-ene-3, 17-dione; pregn-4-ene-3, 20-dione; 4-pregnene-3, 11, 20-trione; 17 α -hydroxypregn-4-ene-3, 20-dione; 17 α, 21-bishydroxypregn-4-ene-3, 20-dione; 17 α, 21-bishydroxypregn-4-ene-3, 11, 20-trione; 11 β,17 α, 21-trihydroxypregn-4-ene-3, 20-dione; 11 beta, 17 alpha, 21-trihydroxypregn-4-ene-3, 20-dione-21-acetate; 21-hydroxy-pregna-4, 9(11), 16-triene-3, 20-dione-21-acetate.

Compared with the prior art, the invention has the following beneficial effects: the inventor screens out 3-ketosteroid-delta with wide substrate spectrum and high activity to most steroid substrates by gene excavation¹Dehydrogenase, with other 3-sterone-delta presently reported in the literature¹The similarity of dehydrogenase is lower than 60 percent, has obvious difference and is a novel 3-sterone-delta¹Dehydrogenase, providing conditions for further research on the evolutionary relationship of the enzyme family, and constructing the highly effective 3-sterone-delta by using genetic engineering technology¹The dehydrogenase gene engineering bacteria provide more gene resources. In particular, the invention uses genetic engineering means to transform the 3-sterone-delta¹Heterologous over-expression of dehydrogenase gene in colibacillus to obtain high-efficiency expression 3-sterone-delta¹Genetically engineered bacteria of dehydrogenases. The gene was establishedThe biological conversion process of engineering bacteria for series 3-keto steroid compounds obtains high yield target products with high substrate feeding concentration, no by-product, conversion rate not less than 94%, short conversion time, less biocatalyst consumption, simple and convenient preparation method, mild conditions, environmental protection and good industrialization prospect.

Drawings

FIG. 1 shows the HPLC chart of the genetically engineered strain BL21-Sat in example 4.1 for transformation of androst-4-ene-3, 17-dione. Wherein, a is a standard product of the product androstane-1, 4-alkene-3, 17-diketone, and b is a conversion sample of the genetic engineering strain BL21-Sat for converting androstane-4-alkene-3, 17-diketone.

FIG. 2 shows the HPLC chart of the sample transformed by genetically engineered strain BL21-Sat in example 4.2 to transform androsta-4, 9(11) -diene-3, 17-dione.

FIG. 3 is an HPLC chart showing a sample of the transformation of pregna-4-ene-3, 20-dione by the genetically engineered strain BL21-Sat in example 4.3.

FIG. 4 is a HPLC chart showing a sample of the transformation of 17 α -hydroxypregn-4-ene-3, 20-dione by the genetically engineered strain BL21-Sat in example 4.4.

FIG. 5 shows an HPLC chart of hydrocortisone transformed by the genetically engineered strain BL21-Sat in example 4.5. Wherein, a is a standard product of the product prednisolone, and b is a transformation sample of hydrocortisone transformed by the genetic engineering strain BL 21-Sat.

FIG. 6 shows the HPLC chart of the genetically engineered strain BL21-Sat in example 4.6 transformed into 21-hydroxy-pregna-4, 9(11), 16-triene-3, 20-dione-21-acetate. Wherein, a is a standard substance of a substrate 21-hydroxy-pregna-4, 9(11), 16-triene-3, 20-diketone-21-acetate, and b is a conversion sample of a genetic engineering strain BL21-Sat for converting 21-hydroxy-pregna-4, 9(11), 16-triene-3, 20-diketone-21-acetate.

FIG. 7 shows an SDS-PAGE pattern after purification of the Sat protein. Wherein, M is a standard protein; 1-breaking the supernatant after induced expression; purifying by using a 2-nickel column.

Detailed Description

The following further illustrates the invention by way of specific embodiments, but should not be construed as limiting the invention.

Example 1: 3-sterone-delta¹Synthesis of dehydrogenase (Sat) Gene and construction of genetically engineered bacterium

1.3-sterone-. DELTA.¹Synthesis of dehydrogenase Gene

Searching for possible 3-sterone-delta from NCBI databases by gene mining techniques¹Dehydrogenases, with a protein sequence identity of between 30% and 80%, with a very conserved FAD binding region at the N-terminus by sequence analysis (GSGX)_5- ₆AX₂AX₃GLX₅E) And conserved amino acid residues exist and are mined fromSaccharopolyspora kobensisPossible 3-sterone-delta¹-a dehydrogenase sequence having the nucleotide sequence set forth in SEQ ID NO: 2, and the coding amino acid sequence is shown as SEQ ID NO: 1 is shown. The nucleotide sequence was synthesized by general biosystems (Anhui) Ltd and ligated to pET21a vector to obtain 3-sterone-. DELTA.¹Recombinant plasmids of dehydrogenases.

2. Transformation of recombinant plasmids

Preparing competent Escherichia coli cells by calcium chloride method.

(1) mu.L of the recombinant plasmid was placed in 50. mu.L of E.coli BL21(DE3) competent cells and ice-cooled for 30 min.

(2) And (3) carrying out heat shock on the mixture in a water bath at 42 ℃ for 45 s, and quickly placing the mixture on ice for 1-2 min.

(3) Adding 600 mu L of fresh LB liquid culture medium, and carrying out shake culture at 37 ℃ for 45-60 min.

(4) And (3) coating 200 mu L of bacterial liquid on the surface of LB solid medium containing ampicillin, and culturing at 37 ℃ for 12-16 h until single colonies appear.

Example 2: 3-sterone-delta¹Inducible expression and purification of the dehydrogenase (Sat)

Preparing 50 mL of seed solution, wherein the culture medium is LB liquid culture medium (peptone 10g/L, yeast powder 5g/L, NaCl 10g/L), picking a single colony of the genetic engineering strain BL21-Sat by using an inoculating loop, inoculating into the culture medium, and culturing at 37 ℃ and 200rpm overnight. Transferring the seed liquid cultured overnight to a fermentation medium (LB medium) with the inoculation amount of 1%, culturing at 37 ℃ and 200rpm until the A is 6000.6-1.0, adding 0.05 mM IPTG, and inducing at 25 ℃ and 200rpm for 10-12 h. Centrifuging at 4 deg.C and 6000rpm to collect thallus, washing with Tris-HCl buffer solution (50mM, pH 8.0) twice, crushing with high pressure homogenizer, centrifuging at 13000rpm to collect supernatant, purifying and recovering target protein by metal affinity chromatography (nickel column), dialyzing to remove imidazole to obtain pure enzyme solution. SDS-PAGE shows that the protein band obtained by purification is single, and the electrophoretic purity is achieved (see figure 7).

Example 3: 3-sterone-delta¹Substrate profile of the dehydrogenase (Sat)

Enzyme activity determination system: the total reaction volume was 0.2 mL, 50mM Tris-HCl pH 8.0, 1.5 mM Phenazine Methosulfate (PMS), 0.12 mM 2, 6-Dichlorophenolindophenol (DCPIP), 0.5 mM of various substrates (obtained by screening the steroid substrate library of the laboratory), and after adding a suitable amount of purified enzyme Sat (8-48 ng), which was purified by the method described in example 2, the change in absorbance at 600nm was measured starting at 30 ℃. The enzyme activity of 1U was defined as the amount of enzyme required to reduce 1. mu. mol DCPIP in 1 min. The results are shown in Table 1.

Example 4: conversion of 3-keto steroid compound by gene engineering strain BL21-Sat

Seed culture: a single colony of the genetically engineered strain BL21-Sat is picked up by an inoculating loop and inoculated into an LB culture medium containing ampicillin, and cultured overnight at 37 ℃ and 200 rpm.

Fermentation induction culture: the seed liquid cultured overnight was transferred to the fermentation medium at an inoculum size of 1%, cultured at 37 ℃ and 200rpm to OD_600nmAdding 0.6-1.0 mM IPTG, and inducing at 25 deg.C and 200rpm for 10-12 hr to obtain fermentation liquid OD_600nmAbout 10.0.

(4.1): androstane-4-alkene-3, 17-diketone is taken as a substrate

And adding androst-4-ene-3, 17-dione powder into 100 mL of the fermentation liquid, wherein the adding concentration is 100 g/L, adding phenazine methyl sulfate 10g/L, and stirring at 30 ℃ for reaction. And reacting for 24 hours, after the reaction is finished, extracting by ethyl acetate, combining organic phases, drying by anhydrous sodium sulfate, removing the solvent under reduced pressure, and detecting by HPLC that the conversion rate of the reaction reaches 99.0%.

(4.2): androstane-4, 9(11) -diene-3, 17-diketone as substrate

Androstane-4, 9(11) -diene-3, 17-diketone dissolved in DMF (10 mL) is added into 100 mL of the fermentation liquid, the feeding concentration is 50 g/L, then phenazine methyl sulfate is added into the fermentation liquid, 5g/L of phenazine methyl sulfate is added, and the mixture is stirred and reacts at the temperature of 30 ℃. And reacting for 24 hours, after the reaction is finished, extracting by ethyl acetate, combining organic phases, drying by anhydrous sodium sulfate, removing the solvent under reduced pressure, and detecting by HPLC that the conversion rate of the reaction reaches 95.5%.

(4.3): pregna-4-ene-3, 20-dione as substrate

Pregna-4-ene-3, 20-dione powder dissolved in ethylene glycol (30 mL) is added into 100 mL of the fermentation liquid, the feeding concentration is 50 g/L, then 2.5 g/L of 1, 4-naphthoquinone is added, and the mixture is stirred and reacted at 30 ℃. And reacting for 24 hours, after the reaction is finished, extracting by ethyl acetate, combining organic phases, drying by anhydrous sodium sulfate, removing the solvent under reduced pressure, and detecting by HPLC that the conversion rate of the reaction reaches 94.4%.

(4.4): takes 17 alpha-hydroxypregna-4-ene-3, 20-diketone as a substrate

Adding 17 alpha-hydroxypregn-4-ene-3, 20-dione dissolved in isooctanol (40 mL) into 100 mL of the fermentation liquid, wherein the feeding concentration is 50 g/L, adding phenazine methyl sulfate 5g/L, and stirring at 30 ℃ for reaction. And reacting for 24 hours, after the reaction is finished, extracting by ethyl acetate, combining organic phases, drying by anhydrous sodium sulfate, removing the solvent under reduced pressure, and detecting by HPLC that the conversion rate of the reaction reaches 94.8%.

(4.5): 11 beta, 17 alpha, 21-trihydroxy pregn-4-ene-3, 20-diketone (hydrocortisone) is taken as a substrate

And (2) adding 11 beta, 17 alpha, 21-trihydroxy pregn-4-ene-3, 20-dione powder into 100 mL of the fermentation liquor, wherein the adding concentration is 60 g/L, adding 2.5 g/L phenazine methyl sulfate, and stirring at 30 ℃ for reaction. And (3) reacting for 6-8 h, extracting with ethyl acetate after the reaction is finished, combining organic phases, drying with anhydrous sodium sulfate, removing the solvent under reduced pressure, and detecting by HPLC that the conversion rate of the reaction reaches 96.5%.

(4.6): 21-hydroxy-pregna-4, 9(11), 16-triene-3, 20-diketone-21-acetate is taken as a substrate

Adding 21-hydroxy-pregna-4, 9(11), 16-triene-3, 20-diketone-21-acetate dissolved in butyl acetate (40 mL) into 100 mL of the fermentation liquid, adding phenazine methyl sulfate at a concentration of 50 g/L, and stirring at 30 ℃ for reaction. And reacting for 24 hours, after the reaction is finished, extracting by ethyl acetate, combining organic phases, drying by anhydrous sodium sulfate, removing the solvent under reduced pressure, and detecting by HPLC that the conversion rate of the reaction reaches 99.0%.

Sequence listing

<110> institute of biotechnology for Tianjin industry of Chinese academy of sciences

<120> 3-sterone-delta 1-dehydrogenase and coding gene and application thereof

<130>

<160> 2

<170> PatentIn version 3.5

<210> 1

<211> 510

<212> PRT

<213> Saccharopolyspora kobensis

<400> 1

Met Ala Ile Trp Asp Asp Glu Cys Asp Val Leu Val Val Gly Ser Gly

1 5 10 15

Gly Gly Ala Leu Thr Gly Ala Tyr Thr Ala Ala Arg Glu Gly Leu Ser

20 25 30

Val Leu Val Val Glu Ala Ala Asp Lys Phe Gly Gly Thr Thr Ala Tyr

35 40 45

Ser Gly Gly Gly Leu Trp Phe Pro Gly Asn Ala Val Leu Lys Arg Ala

50 55 60

Gly Asp Gln Asp Thr Pro Glu Glu Ala Lys Thr Tyr Tyr Arg Ala Val

65 70 75 80

Val Gly Asp Arg Thr Pro Arg Glu Leu Gln Asp Ala Phe Leu Asp Asn

85 90 95

Gly Ala Arg Leu Val Asp Tyr Leu Glu Glu Asp Asp Asp Phe Glu Phe

100 105 110

Ile Val Tyr Pro Trp Pro Asp Tyr Tyr Gly Ser Ala Pro Gly Ala Ser

115 120 125

Ala Thr Gly Arg His Ile Met Pro Met Pro Met Arg Pro Glu Arg Ile

130 135 140

Gly Ser Leu Arg Glu Gln Leu Arg Pro Pro Val Asp Val Asp Arg Ala

145 150 155 160

Gly Ala Pro Leu Pro Asp Leu Leu Val Gly Gly Gln Ala Leu Ile Gly

165 170 175

Arg Leu Leu Leu Ala Leu Ser Lys Gln Asp Ser Ala Arg Leu Arg Arg

180 185 190

Gly Ser Val Cys Asp Glu Leu Leu Thr Ser Asp Gly Gly Val Ile Gly

195 200 205

Ala Val Val Glu Glu Gly Gly Glu Arg Arg Arg Ile Arg Ala Arg Arg

210 215 220

Gly Val Leu Ile Ala Ser Gly Gly Phe Glu Arg Asn Gln Ala Met Arg

225 230 235 240

Thr Glu His Gly Val Pro Gly Ala Ala Arg Asp Thr Met Gly Pro Ala

245 250 255

Glu Asn Leu Gly Lys Ala Ile Arg Ala Gly Ile Asp Val Gly Ala Gly

260 265 270

Thr Asp Leu Met Ala Glu Ala Trp Trp Ser Pro Gly Ile Thr His Pro

275 280 285

Asp Gly Thr Ser Thr Phe Ser Leu Trp Phe Thr Gly Gly Ile Phe Val

290 295 300

Asp Gly Ala Gly Glu Arg Phe Val Asn Glu Ser Trp Pro Tyr Asp Arg

305 310 315 320

Ile Gly Arg Ala Val Leu Asp Arg Leu Gly Ala Gly Arg Met Ala Leu

325 330 335

Pro Phe Trp Met Ile Tyr Asp Asp Arg Glu Gly Glu Arg Pro Pro Val

340 345 350

Arg Ser Thr Ser Val Pro Met Gly Glu Thr Ala Asp Tyr Val Asp Ala

355 360 365

Gly Leu Trp Phe Ser Ala Gly Thr Leu Ala Glu Leu Ala Glu Lys Ile

370 375 380

Gly Val Pro Ala Glu Asn Leu Glu Arg Thr Val Ala Arg Phe Asn Gly

385 390 395 400

Phe Ala Thr Ala Gly Thr Asp Glu Asp Phe His Arg Gly Asp Glu Pro

405 410 415

Tyr Asp Arg Ser Phe Ala Asp Gly Gly Ser Pro Leu Val Pro Ile Glu

420 425 430

Lys Gly Pro Phe His Ala Ala Ala Phe Gly Leu Ser Asp Leu Gly Thr

435 440 445

Lys Gly Gly Leu Arg Thr Asp Ala Arg Ala Arg Val Leu Ser Thr Ser

450 455 460

Gly Glu Val Ile Pro Gly Leu Tyr Ala Ala Gly Asn Ser Met Ala Ala

465 470 475 480

Val Ser Gly Thr Thr Tyr Pro Gly Gly Gly Asn Pro Ile Gly Ser Cys

485 490 495

Met Val Phe Ser His Leu Ala Ala Leu Asp Met Leu Thr Arg

500 505 510

<210> 2

<211> 1533

<212> DNA

<213> Saccharopolyspora kobensis

<400> 2

atggcgatct gggacgacga gtgcgacgtg ctggtggtcg gttccggcgg cggcgcgctg 60

accggggcgt acacggcggc ccgcgagggg ctttcggtgc tggtggtcga ggcggccgac 120

aagttcggcg gcaccacggc gtattccggc ggcggactgt ggttcccggg caacgccgtg 180

ctcaagcggg ccggcgacca ggacaccccg gaggaggcga agacctacta ccgagcggtg 240

gtgggcgacc gcacgccccg cgagctgcag gacgcgttct tggacaacgg tgcccgactg 300

gtcgactacc tggaggagga cgacgacttc gagttcatcg tctacccctg gccggactac 360

tacgggtcgg cgccgggagc cagcgcgacc ggcaggcaca tcatgccgat gccgatgcgg 420

ccggagcgga tcggctcgct gcgggagcag ctccggccac cggtggacgt cgaccgggcg 480

ggcgcaccgc tgcccgacct gctcgtcggc ggccaggcgc tgatcggcag gctgctgctc 540

gcgctgtcca agcaggactc cgcccggctg cggcgcggat cggtgtgcga cgagctgctg 600

acctccgacg gcggcgtgat cggcgcggtg gtcgaggagg gcggtgagcg acggcggatc 660

cgcgcgcggc gcggcgtgct gatcgcctcc ggcgggttcg agcgcaacca ggcgatgcgg 720

accgagcacg gggtgccggg cgcggcgcgg gacacgatgg ggccggcgga gaacctgggc 780

aaggcgatcc gggccgggat cgacgtcggc gcgggcaccg acctgatggc ggaggcctgg 840

tggtcgccgg gcatcaccca cccggacggg acctcgacgt tctcgctgtg gttcaccggc 900

ggcatcttcg tcgacggcgc gggcgagcgc ttcgtcaacg agtcctggcc gtacgaccgg 960

atcggccgcg ccgtcctcga ccgcctcggc gcgggccgga tggcgctgcc gttctggatg 1020

atctacgacg accgcgaggg cgagcggccg ccggtgcgct cgacgagcgt cccgatgggg 1080

gagacggctg actacgtcga cgccgggctg tggttcagcg cgggcacgct ggccgaactc 1140

gcggagaaga tcggtgttcc cgcggagaac ctggagcgga ccgtggcccg gttcaacggt 1200

ttcgcgaccg ccgggaccga cgaggacttc caccggggtg acgagcccta cgaccggtcg 1260

ttcgcggatg ggggctcccc gctggtgccg atagagaagg gcccgttcca cgccgcggcc 1320

ttcggcctct ccgatctcgg caccaagggc ggtctgcgca ccgatgcgcg tgcccgggtg 1380

ctcagcacct cgggcgaggt gatccccggc ctgtacgccg cgggcaactc gatggccgcg 1440

gtcagcggga ccacgtatcc gggcgggggc aacccgatcg ggtcctgcat ggtgttcagc 1500

cacctcgccg cgctggacat gctcacccgc tga 1533

Claims

1. 3-sterone-delta¹-removingCatalase, or its coding polynucleotide, or the gene engineering expression strain containing said coding polynucleotide for delta of 3-keto steroid¹-use in dehydrogenation reactions;

wherein the 3-sterone- Δ¹-the dehydrogenase is as set forth in SEQ ID NO: 1;

and the 3-ketosteroid compound is one of the following compounds: androst-4-ene-3, 17-dione; androst-4-ene-3, 11, 17-trione; androsta-4, 9(11) -diene-3, 17-dione; 17 β -hydroxyandrost-4-ene-3, 17-dione; pregn-4-ene-3, 20-dione; 4-pregnene-3, 11, 20-trione; 17 α -hydroxypregn-4-ene-3, 20-dione; 17 α, 21-bishydroxypregn-4-ene-3, 20-dione; 17 α, 21-bishydroxypregn-4-ene-3, 11, 20-trione; 11 β,17 α, 21-trihydroxypregn-4-ene-3, 20-dione; 11 beta, 17 alpha, 21-trihydroxypregn-4-ene-3, 20-dione-21-acetate; 21-hydroxy-pregna-4, 9(11), 16-triene-3, 20-dione-21-acetate.

2. The use of claim 1, wherein the encoding polynucleotide is as set forth in SEQ ID NO: 2, respectively.

3. The use of claim 1, wherein the genetically engineered expression strain containing the encoding polynucleotide is produced by operably linking the encoding polynucleotide to a multiple cloning site in the starting vector pET-21a and introducing the same into the strain.

4. Use according to claim 3, wherein the starting strain of the genetically engineered expression strain is E.coli.

5. Use according to any one of claims 1 to 4, wherein a 3-keto steroid is used as substrate, an electron acceptor is added, said electron acceptor being phenazine methosulfate or 1, 4-naphthoquinone, and the conversion reaction is carried out to give the C1, 2-dehydrosteroid.

6. The use according to claim 5, wherein the reaction temperature is 25-35 ℃ and the reaction time is 6-24 h.